Cybin Inc. (
NEO.CYBN,
OTC: CLXPF,
Forum) – a biotech company focused on progressing “Psychedelics to Therapeutics™” – has announced that Adelia Therapeutics Inc. – a wholly-controlled subsidiary of Cybin – has achieved the milestones identified as Year 1 Q4, Year 2 Q2, and Year 2 Q3, as contemplated by the terms of a contribution agreement dated December 4, 2020 (the “Transaction Agreement”) among Cybin, Cybin Corp., Cybin US Holdings Inc., a wholly-controlled subsidiary of Cybin, and all of the previous shareholders of Adelia.
Additional information related to the transaction is available in the Transaction Agreement – filed under Cybin’s profile on SEDAR (
www.sedar.com) and with the U.S. Securities and Exchange Commission on EDGAR at
www.sec.gov.
Full story
here.
About Cybin
Cybin is a leading ethical biopharmaceutical company, working with a network of world-class partners and internationally recognized scientists, on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues. Headquartered in Canada and founded in 2019, Cybin is operational in the USA, UK and Ireland. The Company is focused on progressing ‘Psychedelics to Therapeutics’ by engineering proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health disorders.
New to investing in Cannabis? Check out Stockhouse tips on How to Invest in Cannabis Stocks and some of our Top Cannabis Stocks.
For more of the latest info on Cannabis, check out the Cannabis Trending News hub. Or, for lively sector discussion, visit Stockhouse’s new Cannabis Bullboards page.
FULL DISCLOSURE: Cybin Inc. is a client of Stockhouse Publishing.